Pancreaticoduodenectomy for suspected periampullary cancers: the mimes of malignancy  by Hernandez, Jonathan et al.
ORIGINAL ARTICLE
Pancreaticoduodenectomy for suspected periampullary cancers:
the mimes of malignancyhpb_103 578..584
Jonathan Hernandez, Connor Morton, Whalen Clark, John Mullinax, Abishek Mathur, Andrea Marcadis, Nitin Babel,
Sharona Ross, Steven Goldin & Alexander Rosemurgy
Department of Surgery, University of South Florida and Tampa General Hospital Center for Digestive Disorders, Tampa, FL, USA
Abstract
Background: Pancreaticoduodenectomies are often undertaken with suspicion of malignancy. We
undertook this study to determine if and how unnecessary pancreaticoduodenectomies can be avoided.
Methods: Data from patients undergoing pancreaticoduodenectomy were prospectively collected.
Operative indications, including presenting symptoms and results with imaging, with or without biopsy,
were reviewed.
Results: From 1996 through to 2007, 551 patients underwent pancreaticoduodenectomy at our insti-
tution. Chronic pancreatitis was the operative indication in 3% of patients; premalignant/malignant lesions
were present in 86% of patients. Eleven per cent of patients underwent ‘unnecessary’ pancreati-
coduodenectomies with presumptive diagnoses of cancer but were without premalignant/malignant
disease on final report by Pathology [pancreatitis in 63%, serous cystadenomas (<4 cm) in 14%]. Of the
unnecessary resections, 20% had histories and imaging sufficient to diagnose pancreatitis, 18% had
inaccurate preoperative brushings/biopsies ‘documenting’ cancer, 11% had clear misinterpretations of
their imaging studies and 7% had inadequate preoperative evaluations. However, 45% had signs/
symptoms of cancer with a pancreatic head mass/biliary stricture.
Conclusion: Only a small minority of patients undergoing pancreaticoduodenectomy for suspicion of
periampullary cancer do so unnecessarily. Preoperative review of biopsies, better considerations of
pancreatitis and careful evaluation of imaging, particularly for cystic masses, will decrease unnecessary
pancreaticoduodenectomies.
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Radiographical identification of a pancreatic mass in a symptom-
atic patient is often the start of a diagnostic dilemma, which
surgeons are facing with increasing frequency given the almost
ubiquitous use of computed tomography (CT) in today’s health-
care system. Pancreatectomies are often undertaken without
histological confirmation of cancer as definitive diagnoses are
difficult to obtain, and not without risk. Furthermore, a biopsy of
the pancreatic mass is not a prerequisite to operative exploration
in current care algorithms1 given the likelihood of malignancy.
In an analysis of nearly 2000 pancreaticoduodenectomies, 78%
of asymptomatic pancreatic masses resected harboured pre-
malignant and/or malignant disease whereas 76% of symptomatic
masses harboured malignant disease.2 For the subset of patients
with pancreatic adenocarcinoma, survival was significantly
improved for those undergoing resection of cancers before the
onset of symptoms.2 In another study of 212 patients with cystic
pancreatic lesions seen at a single tertiary care centre, almost 60%
hadmalignant and/or premalignant disease, including over half of
the patients seen with a history of pancreatitis.3
Clearly timely intervention is important for patients with
radiographical demonstration of a pancreatic mass. However,
broad application of pancreaticoduodenectomy for suspicions of
malignancy will result in a number of patients undergoing
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unnecessary resections, with attendant risks, for non-malignant
or non-premalignant disease. On the contrary, observation with
serial imaging or bypass procedures for those without definitive
diagnoses of cancer will undoubtedly lead to delays in diagnosis
of malignancy with advances in stage, suboptimal treatments
and, ultimately, shorter survival. We undertook this study to
better define those patients undergoing unnecessary pancreati-
coduodenectomies, which we define arbitrarily for the purposes
of this study, irrespective of any associated symptoms, as those
resections undertaken for suspicion of malignancy that, after final
pathological examination, were without malignant or premalig-
nant disease. Specifically, we sought to gain insight as to how and
why surgeons are misled. Our hypotheses in undertaking this
study were that unnecessary pancreaticoduodenectomies are
infrequent, the majority of patients undergoing unnecessary
pancreaticoduodenectomies could be identified preoperatively
and surgeons would most commonly be led astray by misinter-
pretation of radiographic imaging.
Methods
With institutional review board approval, data were extracted
from a prospectively maintained database on all patients under-
going pancreaticoduodenectomy at our institution. Indications
and preoperative diagnoses for patients undergoing pancreati-
coduodenectomy were determined. Patients undergoing pancre-
aticoduodenectomy for malignancy or suspicion of malignancy
were identified and categorized into two groups based upon final
review by Pathology: patients with disease necessitating pancre-
aticoduodenectomy (i.e. necessary pancreaticoduodenectomy) or
patients with disease not necessitating pancreaticoduodenectomy
(i.e. unnecessary pancreaticoduodenectomy). Final diagnoses
of patients undergoing necessary pancreaticoduodenectomies
are listed in Table 1. Patients undergoing unnecessary pancrea-
ticoduodenectomies were considered to have done so irrespective
of symptoms or the potential need for operative intervention
(e.g. bypass or pancreaticoduodenctomy) as a result of those
symptoms.
The clinical histories, including past medical history as well as
the circumstances prompting presentation, and all pertinent
imaging data were reviewed for patients undergoing unnecessary
pancreaticoduodenctomy. These data were reviewed indepen-
dently by at least two surgeons, at least one of whom was not
involved in the care of the individual patient in question.
Data were analysed utilizing Graphpad Prism 5.0 and Graph-
pad Instat 3.0 (Graphpad Software, San Diego, CA). Comparisons
were undertaken utilizing the Mann–Whitney U-test. Data are
presented as median, mean  standard deviation, where appro-
priate. Significance was accepted with 95% probability.
Results
From 1996 to 2007, 551 patients underwent pancreati-
coduodenectomies at our institution. Of these patients, 17 (3%)
underwent pancreaticoduodenectomy for symptomatic relief
from known chronic pancreatitis and were thus excluded from
further analysis. Malignant disease was identified on final exami-
nation by Pathology in 411 patients and premalignant tumours
were identified in 65 patients (Table 1). These patients were con-
sidered to have undergone pancreaticoduodenectomy out of
necessity and were not analysed further.
Non-neoplastic diseases or neoplastic disease of extremely low
malignant potential were identified upon final examination by
Pathology in 58 (11%) patients. Of note, two patients did not
have sufficient data for evaluation and were thus excluded from
our final analysis. The median age for patients undergoing pan-
creaticoduodenectomy unnecessarily based upon final examina-
tion by Pathology was 58 years, 59  12.1. Presenting symptoms
included pain (61%), jaundice (48%) and weight loss (41%),
and were noted for a median duration of 1.0 month, 5  11.9
prior to pancreaticoduodenectomy. All patients undergoing pan-
creaticoduodenectomy underwent triphasic CT scans utilizing
thin cuts through the pancreas; 36 (64%) had solid masses and
14 (25%) had cystic masses on CT scans (Table 2). Tumour size
was 4.1 cm, 4.1  1.31 for patients presenting with solid masses
and 2.3 cm, 2.1  1.0 for patients presenting with cystic masses.
Multiple symptoms at presentation were noted in 64% of
patients, and 18% presented with a single symptom. Out of 56
patients undergoing pancreaticoduodenectomy for the presump-
tive diagnosis of malignancy, 36 (64%) had pancreatitis noted on
Table 1 Patients undergoing pancreaticoduodenectomy out of
necessity, as defined by final pathological evaluation
Known chronic pancreatitis: 17
Malignant disease: 411
Pancreatic adenocarcinoma (252)
Ampullary adenocarcinoma (65)
Cholangiocarcinoma (49)
Duodenal adenocarcinoma (14)
Pancreatobiliary carcinoma (12)
Islet cell carcinoma (9)
Lymphoma (5)
GI Stromal tumour (3)
Liposarcoma (1)
Squamous cell carcinoma (1)
Premalignant disease: 65
IPMN (18)
Neuroendocrine tumour (18)
Mucinous cystadenoma (14)
Ampullary adenoma (6)
Choledocal cyst (3)
PAN-IN 3 (1)
Serous cystadenoma >4 cm (5)
Patient total: 493
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examination by Pathology. The final diagnoses per Pathology for
patients undergoing pancreaticoduodenectomy unnecessarily are
depicted in Table 3.
Careful review of all data for patients undergoing pancreati-
coduodenectomies without premalignant/neoplastic disease or
malignant disease led to the identification of specific inadequacies
in management or misleading information in the care of these
patients. Patients were then codified along the specific failures in
evaluation and/or management.
Patients with final diagnoses of pancreatitis that
could have and should have been identified
preoperatively with available data
Eleven patients had sufficient clinical histories and imaging char-
acteristics to have yielded a very high suspicion for pancreatitis
(Table 2). Six (55%) of these patients had a history of chronic
pancreatitis, two of whom presented with cystic masses on CT,
which proved to be pseudocysts on final examination by Pathol-
ogy. Five patients had recent episodes of acute pancreatitis or
Table 2 Pertinent radiographical and clinical data for 56 patients evaluated after undergoing unnecessary pancreaticoduodenectomies
based upon final examination by Pathology
All
patients
Patients with
misleading clinical/
imaging indications
Patients with
false-positive
biopsies
Failure to
recognize
pancreatitis
Imaging
misinterpretation
Patients
requiring
further workup
Number of patients (56): 56 25 10 11 6 4
Solid mass: 36 20 4 8 2 2
Cystic mass: 14 1 5 2 4 2
No mass: 6 4 1 1 0 0
Workup:
CT 56 25 10 11 6 4
MR 4 2 0 2 0 0
PET 3 1 1 0 1 0
EUS 10 1 6 0 3 0
FNA 10 1 6 0 2 1
ERCP 28 19 4 2 3 0
History of pancreatitis: 13 4 2 6 0 1
Single symptom: 10 5 1 3 0 2
Multiple symptoms: 36 17 7 6 3 2
Asymptomatic: 10 3 2 2 3 0
Symptoms:
Pain 34 (61%) 18 (72%) 6 (60%) 6 (60%) 1 (17%) 3 (75%)
Jaundice 27 (48%) 15 (60%) 6 (60%) 4 (40%) 2 (33%) 0
Weight loss 23 (41%) 14 (56%) 1 (10%) 3 (30%) 2 (33%) 3 (75%)
Nausea/fatigue 16 (29%) 7 (28%) 4 (40%) 2 (20%) 2 (33%) 1 (25%)
CT, computed tomography; MR, magnetic resonance; PET, positron emission tomography; EUS, endoscopic ultrasound; FNA, fine needle aspiration;
ERCP, endoscopic retrograde cholangiopancreatography.
Table 3 Final diagnosis by Pathology for 56 patients undergoing pancreaticoduodenectomies unnecessarily
Final Pathology Patients with
misleading clinical/
imaging indications
Patients with
false-positive
biopsies
Failure to
recognize
pancreatitis
Imaging
misinterpretation
Patients
requiring
further workup
Total
Pancreatitis 19 4 11 0 2 35 (62.5%)
Serous cystadenoma (<4 cm) 1 2 0 4 0 8 (14%)
No definable Pathology 3 2 0 2 0 7 (12.5%)
Intramuscular duodenal cyst 0 0 0 0 2 2 (3.5%)
Benign biliary stricture 0 2 0 0 0 2 (3.5%)
Bile duct hamartoma 1 0 0 0 0 1 (2%)
Caseating granulomas 1 0 0 0 0 1 (2%)
Total 25 10 11 6 4 56
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recent onset of known precipitating events such as choledoch-
olithiasis. In addition, of the eight patients presenting with a solid
mass, seven had distinct evidence of peripancreatic inflammation
most consistent with pancreatitis. The average duration of symp-
toms prior to operative intervention for these 11 patients was 10
months, 16.4  19.5, which was longer than the symptom dura-
tion experienced by other patients undergoing necessary or
unnecessary pancreaticoduodenectomies (P = 0.01, unpaired
Student’s t-test).
Patients with false-positive preoperative biopsies
Ten patients were referred for pancreaticoduodenectomy with
biopsies documenting adenocarcinoma; each was a false-positive
biopsy based on examination by Pathology of the resected speci-
mens. Of note, seven of these patients had biopsies outside our
facility and were not reviewed within our own institution. Five of
these patients had false-positive fine needle aspirations (FNAs) via
endoscopic ultrasound (EUS); four patients had false-positive
brushings via endoscopic retrograde cholangiopancreatography
(ERCP). One false-positive biopsy was obtained during celiotomy,
pancreatic biopsy, limited resection of the pancreatic head and
lateral pancreaticojejunostomy for chronic pancreatitis. This
biopsy was reviewed, and the presence of cancer was confirmed by
numerous pathologists across the United States prior to reopera-
tion and pancreaticoduodenectomy.
Patients with misinterpretations of imaging
Misinterpretations of imaging occurred in six (11%) patients,
four of whom had cystic masses on CT (Table 2); in each of these
four patients the diagnosis by Pathology was a serous cystad-
enoma less than 4 cm in size (Table 3). The imaging of each serous
cystadenoma was misinterpreted despite characteristic imaging
appearances. Two patients presented with pancreatic head fullness
with abdominal pain and nausea. These two patients had no
definable pathology in their specimen and persistence of symp-
toms after the procedure. Notably, half of the patients were
asymptomatic (Table 2).
Patients requiring further workup
Four patients were identified for whom further workup would
have likely led to the correct diagnosis preoperatively. None of
these four patients were asymptomatic. Preoperative evaluation
and symptoms surrounding presentation are depicted in Table 2.
Two patients presented with a solid mass on computed tomogra-
phy (CT) and were ultimately found to have chronic pancreatitis.
Surgeons felt that a preoperative ERCP or intra-operative ultra-
sound would have yielded the correct diagnosis. These two
patients had pancreatitis associated with pancreatic duct stones
(1) and choledocholithiasis (1). Two additional patients had intra-
muscular duodenal inclusion cysts, which surgeons felt could have
been delineated with the use of intra-operative ultrasonography.
Patients with misleading clinical and/or imaging
indications for pancreaticoduodenectomy
After careful review, 26 patients could not have been identified as
having non-neoplastic pathology or neoplastic pathology not
requiring pancreaticoduodenectomy (e.g. small serous cyst) based
upon evaluation of preoperative data. In other words, surgeons
felt as though these 26 patients would have again warranted pan-
creaticoduodenectomy. All but four (15%) of these patients were
symptomatic at presentation and 72% experienced pain, 60%
experienced jaundice and 56% experienced weight loss (Table 2).
Twenty (80%) of these patients presented with a solid mass on CT
scan, 15 of whom were ultimately diagnosed with pancreatitis
despite lack of corroborating history and precipitating events (no
antecedent history of gallstone disease, alcoholism, recent ERCP,
etc). Five additional patients presented with a solid mass on CT
and ultimately had rare diagnoses such as intrapancreatic biliary
hamartoma (1), intrapancreatic caseating granulomas (1) or no
definable pathology (3) (Table 3). Four patients presented with
biliary strictures causing obstructive jaundice. Each of these four
patients underwent ERCP with brushings, and each cytological
evaluation demonstrated atypical cells. Pancreatitis was the final
pathological diagnosis in each of these four patients. One patient
presented with a cystic mass and abdominal pain, nausea and
fatigue. This patient ultimately proved to have a serous cystad-
enoma on final examination by Pathology despite an atypical
appearance on CT and magnetic resonance (MR) scans.
Discussion
The decision to operate upon patients without confirmation of
cancer potentially places patients at risk for all the complications
associated with an operation without its advantages (e.g.
improved survival). This is particularly true for patients with pre-
sumed pancreatic cancers, given the morbidity associated with
pancreaticoduodenectomy.4–8 Tempering any reluctance to under-
take pancreaticoduodenectomy without confirmation of cancer is
the knowledge that timely pancreaticoduodenectomy provides the
only opportunity for cure of pancreatic adenocarcinoma and the
best opportunity for prolonged survival. On occasion, we have
noted that operative findings or final examination by Pathology
did not justify the pancreaticoduodenectomy undertaken. In
undertaking this study, we have identified the potential to decrease
the number of unnecessary pancreatic resections undertaken at
our institution. Specifically, we have identified the following
avenues to improve the care delivered to patients with undocu-
mented pancreatic neoplasia: (i) re-review of all biopsy/cytology
specimens, (ii) cautious approach to patients with a history of
pancreatitis or known precipitating causing of pancreatits, and
(iii) careful interpretation of radiographical imaging.
Central to any evaluation regarding patient selection for a given
intervention is the safety of that intervention. In other words, the
risk/benefit analysis for each patient, particularly those without
confirmation of disease, must take into account operative mortal-
HPB 581
HPB 2009, 11, 578–584 © 2009 International Hepato-Pancreato-Biliary Association
ity as well as expected post-operative morbidity. With regard to
pancreatic pathology and specifically undertaking pancreati-
coduodencetomy, increasing evidence suggests that morbidity and
mortality can be minimized if the resection is undertaken by high
volume surgeons in high volume centres.9–12 For example, the
mortality rate for patients undergoing pancreaticoduodenectomy
at low volume centres and in specialized centers of excellence are
12% and 2%, respectively.2,13 Therefore, stratification of care to
specialized centres may be particularly appropriate for patients
with suspected solid and cystic pancreatic neoplasms given the
more favourable risk/benefit profile associated with care at these
institutions.
The management of cystic lesions of the pancreas has evolved
along with our understanding of their natural history as well as
improved diagnostic imaging and procedures. The International
Association of Pancreatology reviewed the available literature
regarding intraductal papillary mucinous neoplasms (IPMN) and
mucinous cystic neoplasms (MCN) and defined resection crite-
ria.14 In short, all MCNs andmain duct IPMNs should be resected,
whereas side branch IPMNmay be observed if <3 cm and without
suggestive radiographical features. For the purposes of this study,
we considered all patients with IPMN, irrespective of ductal
origin, to have undergone resection out of necessity given the very
recent clarification of the natural history of this disease and study
time-frame during which patients received treatment. Serous cys-
tadenomas (SCA) are another commonly encountered neoplastic
cyst but are, with few exceptions, low risk for malignancy. There
have been 10 cases of malignant SCA reported in the English
literature and the risk of malignancy has been estimated to be
<3%.15,16 Recently growth rates for SCA have been identified as
being important in the decision process to resect; tumours less
than 4 cm grow 0.12 cm/year whereas those >4 cm grow 2 cm/
year.17 The implications of differential growth rates upon malig-
nant transformation, if any, remain unknown but nonetheless
contribute to management recommendations. Patients with SCA
greater than 4 cm, particularly those associated with symptoms,
are recommended to undergo resection, assuming appropriate
fitness for operative intervention.17,18 For the purposes of this
study, we considered all patients with SCA greater than 4 cm to
have undergone resection out of necessity irrespective of associ-
ated symptoms, although four out of the five patients in the
present study with SCA greater than 4 cmwere symptomatic (data
no shown).
Implicit in the management of various cystic pancreatic lesions
is the ability to accurately diagnose them. Indeed, resection crite-
ria for SCA include the inability to distinguish them from MCN.
This distinction can be particularly problematic for oligocystic
and macrocystic variants of SCA when CT alone is utilized for
diagnosis. However, EUS with FNA may increase our ability to
accurately stratify patients. For example, cyst CEA levels have been
shown to strongly correlate with malignant potential.19,20 Newer
proprietary DNA platforms have also been developed and assign
probability of malignancy based upon measured genetic muta-
tions.21,22 We have tried proprietary DNA platforms without much
success to date. In our study, nearly 70% of patients with cystic
masses undergoing unnecessary procedures did so because of
false-positive preoperative biopsies or imaging misinterpreta-
tions. Our data therefore support those conclusions of Hartwig
et al. in their recent review of the literature regarding the need for
a preoperative tissue diagnosis for tumours of the pancreas; it is
generally not advisable.23
Solid pancreatic lesions can be problematic. The overwhelming
majority of solid masses in the pancreas will be malignant,
particularly when associated with symptoms, making the uncom-
mon benign solid mass difficult to identify preoperatively. Even
although EUS-guided FNA has become standard practice in some
centres, negative or equivocal results are not particularly useful,
baring rare diagnoses such as biliary hamartoma. Pancreatic bio-
psies are subject to sampling error given the intense peritumoral
desmoplastic reaction associated with malignancies and therefore
are far less accurate than when applied to cystic pancreatic lesions.
Although serum CA 19-9 may be a reliable marker for cancer
recurrence after resection, it is an unreliable diagnostic test as
elevations are known to occur with both malignant and benign
pathology and elevations may not occur with malignant disease,
particularly early disease.24 We have identified that the majority of
patients with non-neoplastic solid masses undergoing pancreati-
coduodenectomies for suspected malignancies will ultimately
prove to have pancreatitis. Furthermore, pancreatic malignancies
are not infrequently associated with pancreatitis, either causally or
as a result of long-standing chronic pancreatitis. We have not
found utility in the use of other imaging modalities such as
positron emission tomography (PET) to differentiate benign and
malignant pancreatic lesions, although a standardized uptake
value (SUV) cut-off of 2.0 has been suggested to aid in the differ-
entiation of chronic pancreatitis from pancreatic cancer.25 We
have found a false-negative rate of 20% even in large locally
advanced pancreatic cancers and are very skeptical of negative
PET scans (unpublished data). Others have noted a slightly higher
SUV for pancreatic cancer than chronic pancreatitis, but the false-
positive results are generally prohibitive for use in any definitive
manner.26 However, we have identified 11 patients with a final
diagnosis of pancreatitis, including eight patients with solid
masses, for whom histories and imaging were felt to be sufficient
for a correct preoperative diagnosis. These patients may warrant
aggressive preoperative diagnostics and a short, definable obser-
vation period with repeat imaging rather than dismissal for the
reasons outlined above.
In undertaking this study, we chose to focus on the diagnostic
and clinical data available to the operating surgeon at the time the
procedure was undertaken, and reserved categorization of
patients as needing more workup to the circumstance that the
addition of a specific test was very likely to yield the correct
diagnosis. It is important to note that this study spans over a
decade. Some diagnostic measures are nowmore readily available,
such as EUS with FNA. Notably, it seems that the majority of
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patients undergoing unnecessary pancreaticoduodenectomies did
so prior to our more frequent use of EUS, although most patients
had solid, not cystic, lesions. The study methodology also has
several important inherent biases. Our methodology presumed
that all pancreatectomies without neoplasia were unnecessary; we
defined them as such. It is, however, likely that a number of the
patients in this study required an operation (possibly a pancreati-
coduodenectomy) for symptom relief alone and therefore we may
have inflated the number of patients undergoing unnecessary
resections. In addition, there is the error inherent in any process of
peer-review. In particular, final diagnoses by Pathology were
inevitably made known during the review process, which may
have affected outcome.
In reviewing patients undergoing unnecessary pancreati-
coduodenectomies based upon final diagnoses by Pathology, we
have stratified patients by evaluation of pertinent clinical and
radiographical data in the hope of improving the quality of care
delivered to patients at our institution and to identify the mimes
of malignancy. With vigilant review of biopsy specimens, imple-
mentation and interpretation of evolving imaging diagnostics,
as well as a cautious approach to patients with strong suspicion
for pancreatitis, a large percentage of unnecessary pancreati-
coduodenectomies can be avoided. Even with the implementation
of recommendations based upon the findings of this study, we
recognize that ‘due diligence’ will, nevertheless result in a number
of patients undergoing unnecessary resections, albeit at reduced
rates. In particular, we have identified symptomatic patients pre-
senting with a solid pancreatic mass as problematic, particularly
given that this cohort of patients will contain very few mimes of
malignancy and the majority of the mimes will be unrecognized
until final examination by Pathology.
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